CHEK2 and diffuse large B-cell lymphoma: Moreover, the overexpression of HBx significantly reduces the activation of CHK2 signals induced by S-period blockers and p53 and p21 in patients with HBV-associated DLBCL, consequently reducing the sensitivity of chemotherapy drugs and suggesting that CHK2 may be a potential factor in HBx-induced chemotherapy resistance (54).